Alembic Pharma gets USFDA EIR for Jarod facility
Vadodara: Alembic Pharma has announced that the Company has received an Establishment Inspection Report (EIR) with classification as "Voluntary Action Indicated (VAI)" from the US Food and Drug Administration (USFDA) for the inspection carried out at the Company's Solid Oral Formulation Facility (F-4) at Jarod, Vadodara.
The inspection was conducted from 14th November, 2024 to 22nd November, 2024.
Read also: Alembic Pharma bags USFDA final approval for schizophrenia drug Brexpiprazole
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.